The constitutively active serine/threonine kinase Pim-1 is upregulated in different cancer types, mainly based on the action of several interleukines and growth factors at the transcriptional level. So far, a regulation of oncogenic Pim-1 by microRNAs (miRNAs) has not been reported. Here, we newly establish miR-33a as a miRNA with potential tumor suppressor activity, acting through inhibition of Pim-1. A screen for miRNA expression in K562 lymphoma, LS174T colon carcinoma and several other cell lines revealed generally low endogenous miR33a levels relative to other miRNAs. Transfection of K562 and LS174T cells with a miR-33a mimic reduced Pim-1 levels substantially. In contrast, the cell-cycle regulator cyclin-dependent kinase 6 predicted to be a conserved miR-33a target, was not downregulated by the miR-33a mimic. Seed mutagenesis of the Pim-1 3 0 -untranslated region in a luciferase reporter construct and in a Pim-1 cDNA expressed in Pim-1-deficient Skov-3 cells demonstrated specific and direct downregulation of Pim-1 by the miR-33a mimic. The persistence of this effect was comparable to that of a small interfering RNA-mediated knockdown of Pim-1, resulting in decelerated cell proliferation. In conclusion, we demonstrate the potential of miR-33a to act as a tumor suppressor miRNA, which suggests miR-33a replacement therapy through delivery of miR mimics as a novel therapeutic strategy.
Introduction
MicroRNAs (miRNAs) are important regulators of gene expression, controlling developmental processes like embryonic stem cell differentiation, several metabolic pathways, cell proliferation, apoptosis and stress responses (for reviews see Bartel, 2004; Gangaraju and Lin, 2009) . Like small interfering RNAs (siRNAs), miRNAs are loaded into Argonaute-containing 'RNAinduced silencing complexes' called miRNA ribonucleoprotein complexes (miRNPs) . In general, miRNAs have partial complementarity to their target mRNAs leading to translational inhibition or degradation of the respective mRNA in P-bodies Rehwinkel et al., 2005) . A prerequisite for miRNA interaction with mRNA targets is the so-called 'seed region' covering nucleotides (nt) 2-8 of the mature miRNA strand. This region usually forms a continuous duplex with the target followed by an unpaired region and a second less stringent base-pairing interaction (Lewis et al., 2005; Grimson et al., 2007; Bartel, 2009 ).
Many miRNAs have been identified to be involved in the development of cancer or metastasis, for example miR-21, members of the miR-17-92 cluster or miR-155, and are therefore called oncogenic miRNAs (Esquela-Kerscher and Slack, 2006) . These miRNAs can downregulate targets that are involved in the regulation of apoptosis or cell-cycle progression, such as the phosphatase and tensin homolog (Pten), the transcription factor E2F1 or the apoptotic regulator Bim (for review see Croce, 2009 ). On the other hand, certain oncogenes like the transcription factor c-Myc are involved in the transcriptional regulation of miRNAs (O'Donnell et al., 2005) .
Other miRNAs, for example miR-15a, miR-16-1, let7a and miR-145, have been reported to be able to exert tumor suppressor activity by controlling targets that can inhibit apoptosis or promote cell-cycle progression. The tumor suppressor function of miRNAs is mainly directed against classical oncogenes, including the small G-protein Ras, the transcription factor c-Myc, Bcl-2, or cell cycledependent kinases like Cdk4 and Cdk6 (Cimmino et al., 2005; Iorio et al., 2005; Johnson et al., 2005; Croce, 2009) . Consequently, in several tumors, these miRNAs are downregulated or not expressed at all (Garzon et al., 2009) . For example, miR-15a and miR-16-1 are encoded in the chromosomal region 13q14.3 and loss of this region is the most common genomic aberration in chronic lymphocytic leukemia (Calin et al., 2002) . Likewise, downregulation or loss of expression of these two miRNAs are frequently observed in prostata carcinomas (Bonci et al., 2008) .
Beyond Cdk4 and Cdk6, we are not aware of any other examples of oncogenic kinases regulated by miRNAs, despite the fact that the activities of oncogenic kinases are often deregulated in cancer cells (Amaravadi and Thompson, 2005) . So-called survival kinases such as Akt, which promote anti-apoptotic responses or execute crucial steps in cell cycle progression, have received attention as therapeutic targets (Crowell et al., 2007; Martelli et al., 2007) . This is also true for the Pim-1 kinase that can function in a synergistic manner with cMyc to establish severe forms of B-cell lymphomas (van Lohuizen et al., 1989; Verbeek et al., 1991; Zippo et al., 2007; Zhang et al., 2008) .
Pim kinases belong to the small group of constitutively active kinases (Amaravadi and Thompson, 2005; Qian et al., 2005) , and thus their activity correlates with their cellular expression levels. PIM oncogenes are frequently overexpressed in human hematological malignancies and in several solid tumors, for example in prostate and breast cancer. PIM kinases exert their oncogenic potential through regulating MYC transcriptional activity, cap-dependent protein translation, cellcycle progression as well as through suppression of apoptosis by means of BCL2-associated agonist of cell death (Bad) phosphorylation (for review, see Brault et al., 2010; Nawijn et al., 2011) . Isoforms of Pim kinases include Pim-1, -2 and -3 (each B33 kDa), and utilization of alternative start codons gives rise to additional size variants, that is, 44 kDa (Pim-1; Xie et al., 2006) or 37 and 40 kDa (Pim-2; Fox et al., 2003) , respectively (Amaravadi and Thompson, 2005) . For Pim-1, several phosphorylation targets have been identified, such as Cdc25A (Mochizuki et al., 1999) and p21 (Wang et al., 2002) among others (for review see Bachmann and Mo¨ro¨y, 2005) . So far, the expression of Pim-1 has been found to be regulated mainly at the transcriptional level by the action of several interleukines and growth factors that activate STAT3 and/or STAT5 via Janus kinases (Bachmann and Mo¨ro¨y, 2005) . In contrast, a regulation of Pim-1 by miRNAs, which may well add to the differential expression in tumor versus normal cells, has not been reported.
In this study, we establish Pim-1 as a target of miR33a, a miRNA that has not been implicated in tumor progression so far. Levels of miR-33a were observed to be low in a variety of tested cancer cell lines. Transfection of the myeloid leukemia suspension cell line K562 and the colon cancer adhesion cell line LS174T with a miR-33a mimic resulted in an antiproliferative effect through reduced expression of Pim-1. The potential tumor suppressor activity of miR-33a would extend its hitherto known physiological functions in cholesterol metabolism (Najafi-Shoushtari et al., 2010; Rayner et al., 2010) , and may offer novel options in miRNA-based tumor therapy.
Results
For the present study, we chose the following cell lines: (1) the suspension cell line K562 as a model for high endogenous Pim-1 expression; (2) adherent LS174T cells with moderate Pim-1 levels and representing solid tumors, which can be used for the induction of colon carcinomas in nude mice; and (3) Pim-1-negative Skov-3 cells for ectopic Pim-1 overexpression.
The 3
0 -untranslated region of Pim-1 harbors a conserved binding site for miR-33a Here, we asked the question if the oncogenic kinase Pim-1 might be a target of miRNAs. The analysis of human Pim-1 mRNA for putative miRNA-binding sites by TargetScan 5.1 (Whitehead Institute for Biomedical Research, Cambridge, MA, USA) predicted conserved binding sites for miR-124/506, miR-26a/b, miR-15a/-16-1, miR-24, miR-33a and miR-144 (Figure 1a ). Among those, the highest context score percentile of 98 was predicted for miR-33a. For this miRNA, the seed region from position 2-8 nt and the anchor A (Grimson et al., 2007) are almost completely conserved between human, mouse, rabbit, dog and chicken. Also conserved among all five eukaryotes is an unpaired nucleotide stretch (positions 10-12 nt) following the seed, as well as a second stretch (nt 13-17) complementary to the target, thus perfectly matching the 'Grimson rules' (Grimson et al., 2007; Figures 1b and c, right panels) . We further considered miR-15a/-16-1 as candidate regulators of Pim-1 expression owing to their well-characterized tumor suppressor activities (Cimmino et al., 2005; Aqeilan et al., 2010) . However, both miRNAs were ranked much lower by TargetScan 5.1 (percentile of 50 for miR-15a and 67 for miR-16-1) correlating with a lower adherence to the 'Grimson rules' and a lower evolutionary conservation of the putative miR-15a/-16-1 target site in the Pim-1 3 0 -untranslated region (3 0 -UTR) (Figures 1b and c, left panels) . MiR-124/506, miR-26a/ b, miR-24 and miR-144 were considered less promising (see Supplementary Information and Supplementary Figure S1 ), thus prompting us to mainly focus our studies on the potential Pim-1 targeting by miR-33a.
Profiling of selected miRNAs in K562 and LS174T cells We next quantified the levels of miR-33a in K562 and LS174T cells by the stem-loop primer reverse transcriptase qPCR technique (Chen et al., 2005a) . Our analysis also included the closely related miR-33b, other miRNAs predicted to target the Pim-1 3 0 -UTR (miR-15a/-16-1, miR-24, miR-26a, miR-144; see above), miR-17-5p/-20a highly expressed in K562 cells (Venturini et al., 2007) , and miR-374a as a reference miRNA that shows minimal variability in cell lines, as recommended by Applied Biosystems (Foster City, CA, USA) for TaqMan MicroRNA Assays. Among the analyzed miRNAs with seeds in the Pim-1 3 0 -UTR, expression levels in K562 cells decreased in the order miR-16-1>miR-26a> miR-24>miR-15a4 4miR-33a4 4miR-1444 4miR-33b, and a comparable order (miR-16-1>miR-24>miR-26a >miR-15a4 4miR-33a4 4miR-144, miR-33b) was observed in LS174T cells (Figures 2a and b) . Notably, miR-33a expression was comparably low in both cell lines. Conversely, miR-16-1, to which tumor suppressor functions have been assigned (Cimmino et al., 2005; Aqeilan et al., 2010) , showed relatively high expression miR-33a and cancer M Thomas et al levels in both cell lines. As expected, high levels of the oncogenic miR-17-5p and miR-20a, encoded in the miR-17-92 cluster, were found in K562 and LS174T cells. To address the question if miR-33a levels also tend to be low in other cell lines than K562 and LS174T, we further tested HepG2 and Huh7 (liver carcinoma), Skov-3 (ovarian carcinoma) and Hek293 (embryonic kidney) as a nontumor cell line for miR-33a expression. HepG2 and Huh7 cells were included, since miR-33 was recently reported to contribute to the regulation of cholesterol homeostasis in liver cells (Najafi-Shoushtari et al., 2010; Rayner et al., 2010) . Skov-3 cells were chosen because we considered this cell line as a host for ectopic Pim-1 expression (see below). However, all the additionally tested human cell lines had low miR-33a levels (Figure 2c ), only HepG2 cells showed substantial Pim-1 protein expression (data not shown). Thus, at least for the cell types analyzed so far under standard growth conditions, a direct correlation between miR-33a and Pim-1 levels is not evident. Our finding of similarly low miR-33a levels in Hek293 cells relative to the tested cancer cell lines does not support the idea that tumor cells may further downregulate their miR-33a levels (own observations and Willemijn Gommans, personal communication).
Pim-1, but not Cdk6, is a target of miR-33a The high conservation of the miR-33a-binding site in the 3 0 -UTR of Pim-1 and the relatively low levels of miR33a in all tested cell lines suggested the possibility to reduce Pim-1 overexpression in tumors by transfection of cells with a commercially available modified miR-33a mimic. Indeed, western blots demonstrated a substantial downregulation of Pim-1 by the miR-33a mimic in K562 cells. Notably, no change in Pim-1 expression was observed upon transfection with miR-15a or miR-16-1 mimics, or a nonspecific control mimic ( Figure 3a ). Next, we compared an unmodified synthetic miR-33a mimic, which represents the Dicer processing product of pre-miR-33a (see Figure 3b and http://www.mirbase. org) with the commercial mimic (miR-33a modified) from Thermo Scientific (Schwerte, Germany). The unmodified mimic was also capable of downregulating Pim-1 in K562 cells, but less efficiently than the modified mimic ( Figure 3c ). Consistent with this finding, the unmodified miR-33a mimic led to an only moderate reduction in Pim-1 expression in LS174T cells, while the modified miR-33a mimic resulted in a substantial downregulation of Pim-1 protein levels ( Figure 3d ).
We further asked the question if miR-33a, beyond Pim-1, may also target another cell-cycle regulator, miR-33a and cancer M Thomas et al cyclin-dependent kinase 6 (Cdk6), since Targetscan 5.1 had ranked Cdk6 position three among putative miR33a targets owing to the presence of two conserved target sites in its 3 0 -UTR (Supplementary Figure S2) ; the context score percentile was 98 for target site 1 and 20 for site 2). For comparison, Pim-1 was ranked position 56. Cdk6, as Cdk4, promotes the G1/S transition of the cell cycle in conjunction with D-type cyclins through phosphorylation and thus inactivation of the tumor suppressor protein Rb (Meyerson and Harlow, 1994) . Western blot analysis after transfection of K562 cells with the modified and unmodified miR-33a mimics, however, provided no evidence for downregulation of Cdk6 by miR-33a mimics (Figure 3c ). Recently, p53 and ATP-binding cassette transporter A1 (ABCA1) were published as targets of miR-33a (Herrera-Merchan et al., 2010; Najafi-Shoushtari et al., 2010; Rayner et al., 2010) . Since K562 is a p53-deficient cell line (Zhang et al., 1993) , we were only able to test if p53 may also be downregulated by miR-33a mimics in LS174T cells. However, transfection of miR-33a mimics in several independent experiments provided no evidence for a downregulation of p53 in LS174T cells (Figure 3d ). This observation deviates from the findings of Herrera-Merchan et al.
(2010) obtained in the mouse system, but is consistent with the fact that, in the human system, the two predicted target sites of miR-33a in the p53 3 0 -UTR (Herrera-Merchan et al., 2010) would each include two seed mismatches when paired to miR-33a. Unfortunately, the ABCA1 transporter was hardly detec table in K562 and LS174T cells (data not shown), which also disfavored the use of ABCA1 as a straightforward second model target to demonstrate inhibition by miR-33a in K562 cells.
Pim-1 knockdown by the miR-33a mimic versus siRNA Next, we compared the miR-33a-dependent downregulation of Pim-1 with the knockdown mediated by a Pim-1-specific siRNA (siRNA1130 directed against exon 5, Figure 1a ). While the siRNA transfection resulted in a very efficient knockdown of Pim-1 (Figures  4a and b) , the reduction in Pim-1 protein levels mediated by the modified miR-33a mimic was less profound (Figure 4b) . However, the time dependence of Pim-1 knockdown was similar for the Pim-1-specific siRNA and the miR-33a mimic, with decreased protein levels already visible after 24 h, a maximum reduction being reached after 72 h and lower Pim-1 levels still present at 96 h posttransfection of K562 cells (Figure 4b) . A weaker knockdown by the modified miR-33a mimic is consistent with the general trend of miRNAs to repress expression of individual targets more moderately than siRNAs (Selbach et al., 2008) . To evaluate if the miR-33a target site in the Pim-1 3 0 -UTR can also be accessed by an siRNA to possibly enhance the Pim-1 knockdown effect relative to miR-33a, we further tested siRNA 33a fully complementary to the miR-33a target site. Knockdown efficacy was similar to that caused by the modified miR-33a mimic, as inferred from western blot signal intensities (Figure 4c , cf. lanes 2 and 3). We also tested a modified miR-33b mimic but we were unable to detect any Pim-1 downregulation (data not shown). (Figures 3 and 4) , we cloned the 3 0 -UTR of Pim-1 into a luciferase reporter vector (pGL3 control). K562 cells were cotransfected with this construct and either the modified miR-33a mimic, siRNA 33a targeting the same Pim-1 mRNA sequence or the modified control mimic. A significant >50% reduction of luciferase activity was determined for the modified miR-33a mimic relative to the modified control mimic ( Figure 5 , open bars). Compared with the western blot analysis (Figure 4c ), the siRNA 33a was more efficient than the modified miR-33a mimic in this reporter assay. This may suggest that either the luciferase reporter assay is more sensitive than western blot analysis, or the reporter assay system may somewhat differently respond to targeting by RNAi machineries than the Pim-1 3 0 -UTR in its natural context. (c) Pim-1 knockdown efficacy of the unmodified miR-33a mimic (miR-33a unmod.) was compared with that of a modified miR-33a mimic and the control mimic by western blotting using total protein extracts from K562 cells. After detection of bactin, the membrane was again stripped to detect Cdk6 in the identical samples. The miR-33a mimics had no effect on Cdk6 expression levels although two miR-33a-binding sites are predicted in the Cdk6 3 0 -UTR by TargetScan 5.1 (Supplementary Figure S2) . For further details, see (a). (d) Western blot analysis performed as in (c), but using LS174T cells. As another control of the miR-33a effect on Pim-1, the same protein samples were analyzed for the level of p53 recently reported to be a target of miR-33 in mice (Herrera-Merchan et al., 2010). However, we were unable to detect a significant repression of p53 by miR-33a in LS174T cells, as inferred from several independent experiments. . In all three panels, western blot experiments were conducted with an antibody specific to human Pim-1, and an antibody against b-actin was used as loading control.
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We further scrutinized the specificity of the observed miR-33a effect on Pim-1 expression by mutating the miR-33a seed region in the Pim-1-derived 3 0 -UTR of the luciferase reporter (from 5 0 -ACAATGCA to 5 0 -ACAGTGCG). Indeed, the repression effects observed for the modified miR-33a mimic or siRNA 33a were essentially abrogated in the presence of a mutated seed region ( Figure 5 , gray bars).
Ectopic expression of Pim-1 in Skov-3 cells
To further substantiate that miR-33a specifically and directly represses Pim-1 expression, we transfected the Pim-1-deficient ovarian cancer cell line Skov-3 with a human Pim-1 full-length cDNA. Pim-1 overexpression in Skov-3 cells resulted in Pim-1 western blot signals comparable to those observed in K562 cells (this also holds true for transfection of Hek293 cells with the same cDNA; data not shown). Cotransfection of the Pim-1-specific siRNA and the modified miR-33a mimic, but not the control mimic, resulted in Pim-1 downregulation (Figure 6a ). However, a Pim-1 cDNA variant harboring a mutagenized miR-33a seed (see legend to Figure 5 ) remained responsive to the siRNA whose target site was not affected by the seed mutations, but lost its responsiveness to the miR-33a mimic (Figure 6b ). Likewise, a deletion of the entire Pim-1 3 0 -UTR abolished the observed miR-33a-dependent Pim-1 downregulation (Figure 6c ). Taken together, these findings further support our conclusion that miR-33a is able to specifically and directly suppress Pim-1 mRNA utilization via the identified miR-33a target site in the Pim-1 3 0 -UTR.
A miR-33a mimic decelerates tumor cell proliferation
To address the biological relevance of the observed miR33a effects on Pim-1 expression, we hypothesized that Reporter assay using a plasmid-based luciferase coding region fused to the 3 0 -UTR of Pim-1, either containing the wild-type miR-33a target sequence (wt seed 5 0 -ACAAUGCA, open bars) or a mutated miR-33a target site (mutant seed 5 0 -ACAGUGCG, gray bars). K562 cells were cotransfected with the control mimic, modified miR-33a mimic or siRNA 33a fully complementary to the mir-33a seed plus 11 nt upstream in the Pim-1 3 0 -UTR. Data represent mean values derived from at least three independent experiments; RLU, relative light units (±s.e.m.), normalized to those obtained with extracts from cells expressing the reporter mRNA with the wt seed and cotransfected with the control mimic (first bar on the left). 0 -ACAGUGCG) in the 3 0 -UTR of the full-length Pim-1 cDNA abrogated Pim-1 downregulation by the modified miR-33a mimic, but did not interfere with suppression by the Pim-1-specific siRNA1491; for further details, see (a); for uniformity, the control and Pim-1 siRNA lanes were interchanged in position relative to the original western blot, which is indicated by vertical lines. (c) Deletion of the 3 0 -UTR except for the 3 0 -terminal B400 nt in the Pim-1 cDNA, which removes the binding site for miR-33a, resulted in a loss of Pim-1 downregulation by the modified miR-33a mimic; for further details, see (a); none, no effector siRNA or miRNA transfected. Western blot experiments in (a-c) were conducted with an antibody specific to human Pim-1, and an antibody against b-actin was used as loading control. The same western blot illustrating endogenous Pim-1 levels in K562 cells is shown in all panels for comparison on the left; minus sign (c), no transfection with Pim-1 cDNA plasmid; plus sign, transfected with the Pim-1 cDNA plasmid.
miR-33a and cancer M Thomas et al miR-33a may negatively affect cell proliferation through reduction of Pim-1, since a previous study (Zhang et al., 2008) had suggested a direct role of Pim-1 in regulating K562 cell proliferation. Indeed, under reduced serum conditions (2% fetal calf serum (FCS)), but not in the presence of 10% FCS (Supplementary Figure S3a) , an anti-proliferative effect of the miR-33a mimic was observed in K562 cells (Figure 7a) . Consistently, Pim-1 levels in untreated K562 cells were reduced under these serum starvation conditions (2% FCS; Supplementary Figure S3b , left two lanes). This may suggest that Pim-1 levels need to fall below a threshold concentration, and/ or that growth factors need to be lacking in the medium, to make the cells more sensitive towards miR-33a-mediated Pim-1 repression and thus to allow the detection of anti-proliferative effects in this cell line. In LS174T cells, reduced proliferation upon transfection with the modified miR-33a mimic was already seen in the presence of 10% FCS (Figure 7b) . Again, this could be attributed to the already lower expression levels of Pim-1 in LS174T relative to K562 cells (Supplementary Figure S3b) . In line with the more moderate miRNA effects observed above (see Figure 4b) , analysis of K562 and LS174T cell proliferation upon transfection with Pim-1-specific siRNAs revealed more pronounced effects relative to those obtained with the modified miR-33a mimic. This was indicated by strong siRNAmediated inhibition of cell proliferation in LS174T cells (Figures 7d versus b) and in K562 cells already under 10% FCS conditions (Figure 7c) .
Cell-cycle analysis after miR-33a-or siRNA-mediated Pim-1 knockdown in K562 and LS174T cells provided evidence that a downregulation of Pim-1 results in a delay of cycle progression at the stage of the G2 to M phase transition (data not shown), which is in line with a previous study (Bachmann et al., 2004) . This effect was more pronounced for K562 relative to LS174T cells, without any effects on apoptosis in both cell lines (Supplementary Figure S4) .
Discussion
In this study, we newly establish miR-33a as a miRNA with potential tumor suppressor activity and demonstrate by western blot analysis and reporter assays (Figures 3-6 ) that the oncogenic kinase Pim-1 is an evolutionarily highly conserved, specific and direct target of miR-33a. Likewise, transfection of a miR-33a mimic decelerates proliferation in colon cancer and leukemia cells, and exerts similar effects as Pim-1-specific siRNAs.
Notably, miR-33a had not been implicated in tumor progression so far. In the human system, miR-33a and the second family member miR-33b are encoded in miR-33a and cancer M Thomas et al introns of hSREBP-2 (chromosome 22) and hSREBP-1 (chromosome 17), respectively. Both are key transcription regulators of genes involved in cholesterol biosynthesis and uptake. Recently, it has been reported in two independent studies that miR-33a/b posttranscriptionally repress ABCA1, an important positive regulator of high-density lipoprotein synthesis and reverse cholesterol transport (Najafi-Shoushtari et al., 2010; Rayner et al., 2010) . Tissue-specific miR-33a/b and hSREBP RNA levels were found to be tightly correlated, indicating that both intronic miRNAs are coordinatedly expressed with the pre-mRNA they reside in (Najafi-Shoushtari et al., 2010) . In this context, antagonists of endogenous miR-33 were suggested as a potential therapeutic strategy to mitigate cardiometabolic diseases.
We have demonstrated that endogenous Pim-1 levels can be reduced in K562 and LS174T cells by a miR-33a mimic, siRNA 33a fully complementary to the miR-33a target site, and most efficiently, by two different siRNAs targeting other regions of the Pim-1 mRNA. The knockdown efficiency correlated with the strength of the inhibitory effect on cell proliferation ('gene dose effect,' see Figures 3, 4 and 7) . Thus, these results confirm previous studies, which had shown that the reduction of endogenous Pim-1 levels by RNAi negatively affects the proliferation capacity of the human lung carcinoma cell line H1299, of the prostate cancer cell line PC-3 and of K562 cells (Zhang et al., 2007 (Zhang et al., , 2008 (Zhang et al., , 2010 .
Pim kinases have partially overlapping functions with the survival kinase Akt (Amaravadi and Thompson, 2005) since (1) both kinases directly phosphorylate and inactivate the pro-apoptotic Bad protein (Datta et al., 1997; Aho et al., 2004) , (2) both contribute to maintaining a high rate of protein translation through phosphorylation and inactivation of the translational repressor 4EBP1, either directly in the case of Pim-1 (Chen et al., 2005b; Xia et al., 2009) , or indirectly via Tsc2 phosphorylation by Akt, which triggers 4EBP1 phosphorylation via the mTOR complex 1 (Huang and Manning, 2009) ; (3) Akt and Pim kinases can activate nuclear factor-kB-dependent transcription including that of an array of anti-apoptotic genes (reviewed in Amaravadi and Thompson, 2005) . Thus, Pim kinases may act at some points as a cellular backup system for Akt, while supplementing Akt in other pathways to maintain cell proliferation and survival, such as during cardioprotection where Pim-1 acts downstream of Akt signaling (Muraski et al., 2007) . We have demonstrated that the miR-33a target site in the Pim-1 3 0 -UTR is evolutionary strictly conserved, and Pim-1 suppression by miR-33a is direct and specific. This is a clear indication that Pim-1 is a genuine target of miR33a, although we have not yet identified the biological constellation(s) under which endogenous miR-33a levels increase to an extent where they effectively repress Pim-1 expression. As discussed before, expression of miR-33a is rather low and uniform in the cancerous human cell lines tested here (Figure 2 ), as it is in various human normal and cancerous tissues (Najafi-Shoushtari et al.,
2010; Willemijn Gommans, personal communication).
This is also consistent with our finding that miR-33a levels in human colon samples (matching pairs of normal and tumor tissue) were very similar between normal and tumorous tissue (data not shown). This raises the question under which conditions miR-33a will be substantially upregulated. Since miR-33a expression is coupled to hSREBP-2 expression, a key transcription regulator of genes involved in cholesterol biosynthesis and uptake, it is not unlikely that cellular miR-33a upregulation may link cholesterol metabolism to cell proliferation via miR-33a-mediated repression of Pim-1. It is conceivable that miR-33a-mediated suppression of Pim-1 may be relevant in a specialized biological context such as cardioprotection or embryonic development.
Pim-1 is overexpressed to different extents in tumor cell lines, for example K562 or LS174T, where cell proliferation critically depends on the presence of Pim-1. Furthermore, Pim kinases are overexpressed in a series of human hematological malignancies and in several solid tumors. In the normal cellular context, Pim-1 is weakly or not at all expressed and appears to be largely dispensable, as inferred from the fact that knockout mice with a deletion of all three Pim isoforms (Pim-1, -2, -3) showed only moderate phenotypes (Mikkers et al., 2004) . This qualifies Pim-1 as a promising target for anti-tumor strategies, for example through RNAi, since side effects on healthy tissues are expected to be moderate. In contrast, single knockouts of Akt isoforms (Akt-1, -2, -3) in mice resulted in severe phenotypes (Yang et al., 2004) . This suggests that Pim-1 may be a more attractive target than Akt in tumor therapy.
Beyond the inhibition of Pim-1 on the protein level by small inhibitors or knockdown via siRNAs, we demonstrate in this paper that a therapeutic effect may also be achieved through miR-33a-mediated downregulation of Pim-1. MiRNAs are estimated to have, on average, up to 200 targets, which also opens the perspective to exploit synergistic effects on various targets to efficiently induce apoptosis and/or cell-cycle arrest in tumor cells. Indeed, the concept of miRNA replacement therapy has recently been successfully applied to the tumor suppressing miR-26a in a mouse model of hepatocellular carcinoma (Kota et al., 2009) . This was the first proofof-concept study demonstrating that miRNAs can be used as general anti-cancer compounds. Recently, the Slack group demonstrated the therapeutic potential of let-7 (Trang et al., 2009 ), a miRNA family whose members map to chromosomal regions frequently deleted in lung cancer (Calin et al., 2004) , providing another example of miRNA replacement therapy in cancer treatment. Still, miRNA mimic or anti-miR strategies may also result in adverse effects, arising from the capacity of miRNAs to regulate multiple targets. This may also be true for miR-33a mimics which, beyond the anti-tumor effect via Pim-1 shown in this study, may well elicit aberrations of cholesterol metabolism (Najafi-Shoushtari et al., 2010; Rayner et al., 2010) or exert additional effects on so far unknown miR-33a and cancer M Thomas et al targets. Thus, while we firmly establish the miR-33a/ Pim-1 axis, the suitability of miR-33a mimics as therapeutic molecules remains to be shown and is currently under investigation in our laboratory. In fact, we already have experimental data obtained in a s.c. colon carcinoma xenograft model, showing a significant reduction in tumor growth upon nanoparticle-mediated delivery of miR-33a (Ibrahim et al., 2011) .
Materials and methods

cDNA
The full-length human Pim-1 cDNA was purchased from OriGene (Rockville, MD, USA).
miRNA mimics
Modified miRNA mimics (exact structure and modification pattern not disclosed) were purchased from Thermo Scientific and were based on the sequence of the natural mature miRNA single strands: miR-33a: 5 0 -GUG CAU UGU AGU UGC AUU GCA miR-15a: 5 0 -UAG CAG CAC AUA AUG GUU UGU G miR-16-1: 5 0 -UAG CAG CAC GUA AAU AUU GGC G negative control mimic (C-mimic) sold by Thermo Scientific for this purpose: 5 0 -UCA CAA CCU CCU AGA AAG AGU AGA miR-33b: 5 0 -GUG CAU UGC UGU UGC AUU GC Unmodified miR-33a and miR-33b mimics were purchased from MWG (Eurofins MWG Operon, Ebersberg, Germany). Both represent the double-stranded Dicer processing product of pre-miR-33a and pre-miR-33b as published in miRBase/ release14 (http://www.mirbase.org), but lacking the 5 0 -terminal phosphates. siRNAs siRNAs were purchased from Thermo Scientific:
Pim-1 siRNA1130: 5 0 -GAU AUG GUG UGU GGA GAU AdTdT (sense) and 5 0 -UAU CUC CAC ACA CCA UAU CdTdT (antisense); Pim-1 siRNA1491: 5 0 -GGA ACA ACA UUU ACA ACU CdTdT (sense) and 5 0 -GAG UUG UAA AUG UUG UUC CdTdT (antisense); VR1 siRNA (VsiRNA1; Gru¨nweller et al., 2003) as negative control siRNA: 5 0 -GCG AUC UUC UAU UCA ACdT dT (sense) and 5 0 -GUU GAA GUA GAA GAU GCG CdTdT (antisense); siRNA 33a (siRNA directed against the miR-33a target site in the Pim-1 3 0 -UTR): 5 0 -AAA AUG CAC AAA CAA UGC AdT dT (sense) and 5 0 -UGC AUU GUU UGU GCA UUU UdTdT (antisense). Negative control siRNAs for transfection of LS174T cells: a) siRNA-luc (targets luciferase mRNA): 5 0 -CUU ACG CUG AGU ACU UCG AdTdT (sense) and 5 0 -UCG AAG UAC UCA GCG UAA GdTdT (antisense).
Antibodies
Antibodies against Pim-1 (sc-13513), b-actin (sc-47778), Cdk6 (sc-177), p53 (sc-126), ABCA1 (ab-18180) as well as the secondary antibodies (sc-2004: goat anti-rabbit IgG HRPconjugated; sc-2005: goat anti-mouse IgG HRP-conjugated) were from Santa Cruz Biotechnology (Heidelberg, Germany) except for the ABCA1 antibody purchased from Abcam (Cambridge, UK).
Plasmid construction, seed mutagenesis and luciferase reporter assay The full-length Pim-1 cDNA clone was purchased from OriGene (Cat. No.: SC110975, Accession No.: NM_002648.2 hsa Pim-1 oncogene, vector pCMV6-XL4, vector size 4.7 kb plus 2.6 kb Pim-1 insert DNA). To construct the plasmid lacking two thirds of the 3 0 -UTR (including the miR-33a target site), 1 mg of full-length Pim-1 cDNA was digested with the HindIII fast digest enzyme (Fermentas, St Leon-Roth, Germany) to remove the B0.9 kbp HindIII/HindIII fragment of the 3 0 -UTR, followed by vector religation. HindIII cleaves B50 bp downstream of the Pim-1 stop codon (position 1424 in sequence NM_002648.3, see Figure 1a ) and B400 bp upstream of the poly(A) tail (position 2311). The Pim-1 cDNA clone containing the mutation in the miRNA-33a target site was derived from the existing 'pGL3 control Pim-1 3 0 -UTR mut 33a plasmid' (see below). For this purpose, the latter plasmid was also digested with HindIII, and the B0.9 kbp HindIII/HindIII fragment containing the mutation in the miRNA-33a site was cloned into the Pim-1 cDNA clone (from OriGene, see above). The 3 0 -proximal 450 nt (including the miR-33a seed region) of all Pim-1 cDNA constructs (full-length wild-type, Pim-1 D 3 0 -UTR and fulllength cDNA with mutated miR-33a seed) were verified by DNA sequencing.
The 3 0 -UTR of human Pim-1 was cloned into the pGL3 control luciferase reporter vector (Promega, Mannheim, Germany) via its XbaI site. The 3 0 -UTR was initially amplified from K562 genomic DNA with the forward primer 5 0 -GCT CTA GAG CTG TCA GAT GCC CGA GGG and reverse primer 5 0 -GCT CTA GAG CAA TAA GAT CTC TTT TAT TCC CCT GT (XbaI sites underlined). Two G-C base pairs were introduced beyond the XbaI sites for more efficient XbaI digestion of the PCR product. PCR mutagenesis of the miRNA-33a target site was carried out according to Brennecke et al. (2005) using the following primers (sites of mutation underlined): 5 0 -AAA AAA TGC ACA AAC AGT GCG ATC AAC AGA AAA GCT; 5 0 -AGC TTT TCT GTT GAT CGC ACT GTT TGT GCA TTT TTT. Mutations were verified by DNA sequencing.
A total of 5 mg of pGL3 derivatives were cotransfected with 1 mg of miRNA mimics per 1 Â 10 6 K562 cells. After 48 h, luciferase assays were performed using the Promega Luciferase Assay System. Briefly, cells were lysed in 100 ml lysis buffer, and 10 ml of lysate was mixed with 25 ml substrate solution and immediately measured with a Safire2 microplate reader (Tecan, Crailsheim, Germany) in 96-well plates.
